Self-Assessment Post-Test
Self-Assessment Post-Test
RIUPost-Test(Sanofi)_12-05.qxd 12/5/06 6:22 PM Page S43 SELF-ASSESSMENT POST-TEST Advances in Alpha-Blocker Therapy in the Management of Urological Disorders 1. Which subcategory of male ejaculatory disorders is the most prevalent and treated successfully with selective serotonin reuptake inhibitors? a. delayed ejaculation b. premature ejaculation c. retrograde ejaculation d. anejaculation/anorgasmia 2. Which -blocker has the greatest affinity for the 5-HT1a and D2-like receptors? a. alfuzosin b. doxazosin c. tamsulosin 3. Which of the following items is not recommended by the updated American Urological Association Guidelines (AUA) for the treatment of benign prostatic hyperplasia (BPH) as part of a routine initial patient evaluation? a. measurement of prostate-specific antigen levels b. urinalysis c. completion of a validated symptom index d. measurement of serum creatinine levels 4. The panel for the updated AUA Guidelines for the treatment of BPH reviewed which of the following? a. a new meta-analysis of outcome data from before and after 1994 b. published randomized, controlled trials performed after 1994 c. unpublished raw data d. input from numerous sources, including family physicians, urologists, and surgeons e. all of the above 5. The primary reason tamsulosin is prescribed over terazosin and doxazosin is: a. its greater efficacy and better tolerability b. its lack of need for dose titration c. its 10-fold greater selectivity for the 1a subtype over the 1b subtype d. All of the above 6. Which of the following is not true of the sustainedrelease formulation of alfuzosin? a. radioligand binding studies show receptor selectivity for the 1a subtype over the 1d subtype b. its ability to eliminate dose titration is most likely due to its slow-release formulation c. it causes less ejaculatory dysfunction than tamsulosin d. it has minimal effects on blood pressure 7. In several randomized, placebo-controlled trials using the National Institutes of Health–Chronic Prostatitis Symptoms Index, -blockers have proven to be effective in treating which one of the following categories of prostatitic syndromes? a. Category I (acute bacterial prostatitis) b. Category II (chronic bacterial prostatitis) c. Category III (chronic prostatitis/chronic pelvic pain syndrome) d. Category IV (asymptomatic inflammatory prostates) 8. Which one of the following -blockers is presently being studied in a 12-week trial of 280 -blocker– naïve men with a recent diagnosis of chronic prostatitis/chronic pelvic pain syndrome? a. alfuzosin b. tamsulosin c. terazosin d. prazosin 9. The highest concentration of -adrenergic receptors in the human ureter is located in: a. the middle ureter b. the distal ureter c. the proximal ureter 10. The likely mechanism -blockers use to facilitate stone passage is to: a. increase ureteral spasm, increase pressure proximal to stone, relax ureter around and distal to stone b. decrease ureteral spasm, decrease pressure proximal to stone, relax ureter around and distal to stone c. decrease ureteral spasm, increase pressure proximal to stone, relax ureter around and distal to stone VOL. 8 SUPPL. 4 2006 REVIEWS IN UROLOGY S43 RIUPost-Test(Sanofi)_12-05.qxd 12/5/06 6:22 PM Page S44 EVALUATION FORM Advances in Alpha-Blocker Therapy in the Management of Urological Disorders Project ID: 4271 ES 13 Postgraduate Institute for Medicine (PIM) respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this evaluation form. You must complete this evaluation form to receive acknowledgment of participation for this activity. Please answer the following questions by circling the appropriate rating: 5 = Outstanding 4 = Good 3 = Satisfactory 2 = Fair 1 = Poor EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED OBJECTIVES Upon completion of this activity, participants should be better able to: • Differentiate the properties of alpha-blockers for treating BPH • List the AUA Guidelines for Treating BPH • Explain the mechanisms for anejaculation secondary to alpha-blockers • Describe appropriate use of alpha-blockers for treating LUTS unrelated to BPH • Describe appropriate use of alpha-blockers in management of nephrolithiasis 5 5 5 5 5 4 4 4 4 4 3 3 3 3 3 2 2 2 2 2 1 1 1 1 1 5 5 5 5 4 4 4 4 3 3 3 3 2 2 2 2 1 1 1 1 OVERALL EFFECTIVENESS OF THE ACTIVITY • • • • Was timely and will influence how I practice Will assist me in improving patient care Fulfilled my educational needs Avoided commercial bias or influence IMPACT OF THE ACTIVITY The information presented: (check all that apply) ❒ Reinforced my current practice/treatment habits ❒ Will improve my practice/patient outcomes ❒ Provided new ideas or information I expect to use ❒ Enhanced my current knowledge base Will the information presented cause you to make any changes in your practice? ❒ Yes ❒ No If yes, please describe any change(s) you plan to make in your practice as a result of this activity: How committed are you to making these changes? 5 (Very committed) 4 3 2 1 (Not at all committed) FUTURE ACTIVITIES Do you feel future activities on this subject matter are necessary and/or important to your practice? ❒ Yes ❒ No Please list any other topics that would be of interest to you for future educational activities: FOLLOW-UP As part of our ongoing continuous quality-improvement effort, we conduct post-activity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey: ❒ Yes, I would be interested in participating in a follow-up survey. ❒ No, I’m not interested in participating in a follow-up survey. Additional comments about this activity: POST-TEST ANSWER KEY 1___ 2___ 3___ 4___ 5___ 6___ 7___ 8___ 9___ 10___ Request for Credit Name Organization Address Telephone Fax If you wish to receive acknowledgment of participation for this activity, please complete the post-test by selecting the best answer to each question, complete this evaluation verification of participation and FAX to: 303-790-4876. Degree Specialty City, State, Zip E-Mail I certify my actual time spent to complete this educational activity to be: ❒ I participated in the entire activity and claim 1.75 credits. ❒ I participated in only part of the activity and claim _____ credits. Signature S44 VOL. 8 SUPPL. 4 2006 Date Completed REVIEWS IN UROLOGY